These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12672605)

  • 1. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.
    Dufes C; Olivier JC; Gaillard F; Gaillard A; Couet W; Muller JM
    Int J Pharm; 2003 Apr; 255(1-2):87-97. PubMed ID: 12672605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.
    Dufes C; Gaillard F; Uchegbu IF; Schätzlein AG; Olivier JC; Muller JM
    Int J Pharm; 2004 Nov; 285(1-2):77-85. PubMed ID: 15488681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
    Gao X; Wu B; Zhang Q; Chen J; Zhu J; Zhang W; Rong Z; Chen H; Jiang X
    J Control Release; 2007 Aug; 121(3):156-67. PubMed ID: 17628165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration.
    Cui X; Cao DY; Wang ZM; Zheng AP
    Pharmazie; 2013 Jan; 68(1):69-74. PubMed ID: 23444784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passage of vasoactive intestinal peptide across the blood-brain barrier.
    Dogrukol-Ak D; Banks WA; Tuncel N; Tuncel M
    Peptides; 2003 Mar; 24(3):437-44. PubMed ID: 12732342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution of liposomal 131I-VIP in rat using gamma camera.
    Refai E; Jonsson C; Andersson M; Jacobsson H; Larsson S; Kogner P; Hassan M
    Nucl Med Biol; 1999 Nov; 26(8):931-6. PubMed ID: 10708307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoradiographic analysis of the distribution of vasoactive intestinal peptide binding sites in the vertebrate central nervous system: a phylogenetic study.
    Dietl MM; Hof PR; Martin JL; Magistretti PJ; Palacios JM
    Brain Res; 1990 Jun; 520(1-2):14-26. PubMed ID: 2169952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration.
    Ohmori Y; Onoue S; Endo K; Matsumoto A; Uchida S; Yamada S
    Life Sci; 2006 Jun; 79(2):138-43. PubMed ID: 16458931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain.
    Martin JL; Dietl MM; Hof PR; Palacios JM; Magistretti PJ
    Neuroscience; 1987 Nov; 23(2):539-65. PubMed ID: 3437978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the chemical and biological stability of vasoactive intestinal peptide.
    Cui X; Cao D; Qu C; Zhang X; Zheng A
    Drug Dev Ind Pharm; 2013 Dec; 39(12):1907-10. PubMed ID: 22670886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog.
    Thakur ML; Aruva MR; Gariepy J; Acton P; Rattan S; Prasad S; Wickstrom E; Alavi A
    J Nucl Med; 2004 Aug; 45(8):1381-9. PubMed ID: 15299065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system.
    Wu D; Pardridge WM
    J Pharmacol Exp Ther; 1996 Oct; 279(1):77-83. PubMed ID: 8858978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.
    Thorne RG; Pronk GJ; Padmanabhan V; Frey WH
    Neuroscience; 2004; 127(2):481-96. PubMed ID: 15262337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.
    Pallela VR; Thakur ML; Chakder S; Rattan S
    J Nucl Med; 1999 Feb; 40(2):352-60. PubMed ID: 10025846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro autoradiographic localization of vasoactive intestinal peptide (VIP) binding sites in the rat central nervous system.
    Besson J; Dussaillant M; Marie JC; Rostene W; Rosselin G
    Peptides; 1984; 5(2):339-40. PubMed ID: 6089133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.
    Hassan M; Refai E; Andersson M; Schnell PO; Jacobsson H
    Nucl Med Biol; 1994 Aug; 21(6):865-72. PubMed ID: 9234336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation.
    Stark B; Andreae F; Mosgoeller W; Edetsberger M; Gaubitzer E; Koehler G; Prassl R
    Eur J Pharm Biopharm; 2008 Sep; 70(1):153-64. PubMed ID: 18555674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.
    Bickel U; Yoshikawa T; Landaw EM; Faull KF; Pardridge WM
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2618-22. PubMed ID: 8385339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct transport of VEGF from the nasal cavity to brain.
    Yang JP; Liu HJ; Cheng SM; Wang ZL; Cheng X; Yu HX; Liu XF
    Neurosci Lett; 2009 Jan; 449(2):108-11. PubMed ID: 18996442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles.
    Wernig K; Griesbacher M; Andreae F; Hajos F; Wagner J; Mosgoeller W; Zimmer A
    J Control Release; 2008 Sep; 130(2):192-8. PubMed ID: 18601963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.